West China Hospital signed an agreement with Mayo Clinic to transfer to the latter its bioartificial liver patent on October 25th . The agreement involves the transfer of " artificial liver " bedside treatment equipment, including bioartificial liver system and fluidized bed bioreactor to Mayo Clinic. This is the first time that Mayo Clinic has signed a patent transfer agreement with a mainland Chinese hospital. Mayo Clinic is the No.1 hospital overall in the U.S.A. Being developed by Professor Scott L. Nyberg of Mayo Clinic, SRBAL (Spheroid Reservoir Bioartificial Liver) is one of the most advanced BAL systems in the world, and is in the stage of laboratory to market transformation.
One of the two patents transferred to Mayo Clinic this time is the whole blood perfusion bioartificial liver system which is safe, reliable and efficient, ensuring uninterrupted treatment. At the same time, it integrates nutritional support and artificial kidney function to provide more effective support for patients with liver failure. The fluidized bed bioreactor can make more efficient use of the space in the container, and reduce the use of the medium by over50%. In addition, the structure is simplified and more reasonable, which is conducive to industrial production. The use of these two technologies in SRBAL can reduce the cost of treatment by more than 60%.
According to the agreement, Mayo Clinic will apply both technologies to SRBAL system, which will speed up the implementation of "bioartificial liver" equipment patent, realize clinical development and marketing, and benefit more patients with liver diseases. On the other hand, West China Hospital is now able to develop shoulder to shoulder with the world-class team in the field of "bioartificial liver" through its patent transfer with Mayo Clinic. In the future, West China Hospital will continue to participate in the preclinical research of the project, accumulate data, and build its West China brand in the field of "bioartificial liver".
